Wanbury Ltd

Analyst Notes

The lead analyst's read before the data. First-person, opinionated, and labelled [Analyst View] throughout unless a number is tagged otherwise.

Things to think about while reading the rest

Reconciliation register — contested figures and the single value used in this report

Every figure below appears in more than one input with different values. This report uses the value in the "Used" column everywhere; alternates are shown for transparency. Highest authority: lead-analyst primary checks (verified_primary), then audited AR, then financials module, then other modules.

Business Deep-Dive

Products, processes, plants, approvals, IP, people. Tags: [Fact] company filing/exchange disclosure · [Third-party] media/analyst not confirmed by company · [Est.] analyst inference.

API portfolio — molecule by molecule

AR26 MD&A commercial list: Metformin HCl, Metformin HCl DC, Sertraline HCl, Tramadol HCl, Mefenamic Acid, Diphenhydramine Citrate, Diphenhydramine HCl, Paroxetine and an Anaesthetic API [Fact]. The IP's "6 products, 100% chronic portfolio" label is loose — tramadol, mefenamic acid and DPH are largely acute/OTC. Guaifenesin is not a Wanbury molecule (absent from AR26, IP and all web results).

Pipeline (target: ~4 commercial launches a year from FY27)

• Stated therapy coverage: anti-diabetic, anti-depressant, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, gastric-ulcer. Infomerics lists planned launches: anaesthetic, anti-cough, diabetes, blood-thinner from Q4 FY26, worth ₹60–70 Cr of incremental annual revenue. [Fact]
• Selection criteria (IP slide 20): small-to-mid volume molecules; double-digit market share; requests from "marquee clientele"; ~50% gross margin. Longer-term: supply patented molecules' supply chains "beyond FY29–30".
• Track record so far: one launch (the anaesthetic) in FY26 vs a target of four a year from FY27. No commercial FY27 new-molecule revenue disclosed by Oct-2026.

Domestic branded formulations

Brands, product by product

How they make it — processes, technology, inputs

• Process: multi-step synthetic organic chemistry in batch reactors — reaction → crystallisation → centrifugation (pusher centrifuges) → drying (fluid-bed dryers/processors) → milling (pin mill) → solvent recovery (methanol distillation columns). DC grade adds granulation and blending (FBP, 5-T blender). [Fact, AR26 Annex VI]
• Chemistry capabilities (IP slide 19): azidation, bromination, cyanation, chiral chemistry, optical resolution (sertraline cis-(1S,4S) isomer), demethylation, Grignard (tramadol), sodium-metal reactions, metal-hydride reductions, Friedel-Crafts, nitration, hydrogenation, high-pressure reactions, high-vacuum distillation; polymorph control (sertraline Forms I & II), hydrates, hygroscopic handling, DC grades.
• Systems: SAP S/4HANA (RISE with SAP, Deloitte) live 3-Oct-2025; platforms for sourcing, QC, GPS field-force tracking. No technology imported in last 3 years.

Key raw materials by route [Est., standard published routes — company does not disclose]

Facilities

Certifications, regulatory assets, IP and export footprint

• DMF/CEP portfolio: 64 approved + 6 under review = 70 across USA, Europe, Brazil (CADIFA), Korea, Mexico, RoW; best reading 22 US DMFs. Intelsense cites "27+ DMFs" on a different basis. [Fact, IP slide 18]
• Patents: "two granted patents (Sertraline HCl and Carvedilol)" [Third-party, Intelsense]. R&D mandate includes "Novel Platforms for Speciality Generics and IPR". R&D spend not disclosed (AR line blank).
• EHS: ZLD plants, ETPs, HAZOP studies, OCEMS at Patalganga boiler.
• Export footprint: 50+ countries on 4+ continents (older material 60–70+); principal markets US, EU, Brazil, South Korea, Australia. FOB exports ₹463.2 Cr in FY26 (+14.2% vs ₹405.7 Cr). 1996 alliance with Wyckoff Chemicals (US) marketed Wanbury APIs in the US.

Operating leadership

Turnaround history (why the business looks the way it does)

Peak obligations ~₹700 Cr including the Wanbury Holding B.V. guarantee → CDR → loans assigned to Edelweiss ARC (FY17, Dec-2021) → 2020 Cipla brand sale (₹87 Cr) → ₹50 Cr preferential issue (2021) → EARC settlement ₹85 Cr (Dec-2021) → ₹95 Cr Neo AIF NCDs (Jul-2023) clear all legacy lenders → ₹175 Cr + ₹25 Cr 12.5% NCDs (Feb-2025/FY26) → <10% NBFC refinance (Jul-2026). Legacy entities Wanbury Holding B.V. (NL), Ningxia Wanbury Fine Chemicals (China, set up 2008 with Bravo Healthcare for RM sourcing), Wanbury Global FZE (UAE) deregistered 1-Apr-2025; Cantabria Pharma S.L. (Spain, acquired 2007) "under liquidation". Full chronology in Tab 6. [Fact]

Segment Analysis

Wanbury reports one Ind AS 108 segment ("Pharmaceutical and related products"). API vs formulations revenue appears only in MD&A and investor decks; segment EBITDA has never been disclosed. Geography is audited (Notes 47/59).

Annual segment revenue and group margins (₹ Cr)

Sources: IP slides 14, 23, 33 (FY21–FY25) and AR26 (FY26) [Fact]. The IP series shows FY24 total 575.7; audited FY24 is 577.74 (used here). EBITDA "incl. OI" is the company/IP basis; "excl. OI" is this report's headline basis (Tab 5). API + formulations do not foot exactly to total because of other operating revenue and rounding. CAGRs [Est.].

Audited three-year revenue split (Note 34, ₹ Cr)

FY26 composition detail: finished goods ₹568.3 Cr, traded goods ₹75.6 Cr, export incentives ₹0.22 Cr, scrap ₹0.48 Cr, FX gain in revenue ₹5.65 Cr. [Fact]

Quarterly segment view (₹ Cr; company/IP EBITDA basis incl. other income)

H1 FY26: API ₹277 Cr vs ₹256 Cr (+8.2%); formulations ₹40–41 Cr vs ₹34 Cr (+17.6%); H1 GM 56.1% vs 50.2%. Quarters sum to FY26: revenue ≈ 650.2, EBITDA (incl. OI) ≈ 107.7, PAT ≈ 66.2. [Fact, IP slides 27–29; Q3 release; Sahi/Arthneeti; Equitybulls/ScanX]

Geography (audited; revenue from contracts with customers, ₹ Cr)

• Exports = 72.9% of FY26 contract revenue; Brazil ~14%, mostly sertraline [Est.]. FY24 geography not available on a standalone basis (no 3-year audited series).
• Domestic API fell [Est.]: traded-goods basis (174.49 − 75.59) = ₹98.9 Cr vs ₹108.8 Cr (−9.1%); AR formulations basis ₹97.6 Cr vs ₹113.4 Cr (−13.9%). Unquantified formulation exports would narrow the gap.
• FX earnings (FOB exports) ₹463.2 Cr; CIF raw-material imports ₹74.4 Cr.

Fastest grower, segment under pressure, management focus

Financials — Profit & Loss

₹ Cr, standalone. EBITDA definition throughout: operating EBITDA = revenue from operations − COGS − employee − other expenses; excludes other income and exceptional items (same basis as Infomerics Mar-2026: FY24 72.09, FY25 76.32/76.42). The IP and Infomerics Oct-2024 include other income and run higher (FY24 72.99; FY25 IP 79.81). Screener's consolidated series stops at FY25 and differs (FY24 consolidated PAT 56 vs 30.4 standalone; FY23 consolidated sales 485 vs 500) — not used.

Five-year annual P&L (FY22–FY26)

FY24–FY26 [Fact] from FY25/FY26 ARs (FY26 AR restated FY25: FY25 AR originally showed employee 104.24, other expenses 124.49 — regrouped). Gross profit, EBITDA, EBIT [Est.] from audited lines. FY22–FY23 from IP 5-year snapshot (Nov-2025) and Infomerics; Infomerics Oct-2024 shows FY23 EBITDA 23.49 incl. OI (4.70%). FY23 D&A residual (24.09 − 12.38 − 9.69 + 10.40 = 12.42). FY23 finance cost unresolved (12.38 IP vs ~21 Screener/Infomerics — likely classification of part of the ₹9.8 Cr EARC settlement loss); PBT −10.40 consistent across sources. AR-reported FY26 net profit margin 10.72% (FY25 5.09%).

Cost lines and composition (FY26)

One-time and non-cash items called out

Last 8 quarters plus base quarter (standalone, ₹ Cr)

[Fact] Screener standalone quarterly; growth [Est.]. *Q4 FY26 other income −3.39 includes the −3.60 Labour Code exceptional (FY26 quarters sum −2.66 = 0.94 OI − 3.60). Q4 FY26 PAT benefits from deferred-tax remeasurement (tax rate −43%). IP EBITDA (incl. OI) differs slightly, e.g. Q2 FY26 25.98 vs 25.78. Base-quarter comparators: Q1FY24 rev 146.29 / EBITDA 13.35 / PAT 4.69; Q2FY24 144.46 / 17.34 / 7.36; Q3FY24 145.50 / 21.15 / 10.27; Q4FY24 139.41 / 18.16 / 8.08.

Q1 FY27 — what happened

Revenue growth decomposition and margin trend analysis

• Organic vs inorganic: 100% organic — no acquisitions since 2007; the 2020 Cipla brand sale shrank formulations. [Fact]
• Volume vs price: not disclosed in aggregate. Molecule data: FY25 sertraline value +15% / volume +14%; tramadol +25% / +20%; DPH +17% / +20%; FY26 metformin DC volume +7%. Metformin global prices (India) rose from ~US$9.5/kg (Q1-25) to US$10.7/kg (Q2-26), but realisations are not disclosed. [Fact]
• Margin drivers FY23→FY26: COGS fell from 60.6% to 42.5% of revenue (yields, solvent recovery, procurement, stable RM prices). Employee cost rose to 18.4% and other expenses to 22.7% of revenue, absorbing part of the gross gain. Finance cost fell 19% in FY26 on the 12.5% NCDs. [Est.]
• Seasonality: no clear pattern; Q3 FY25 and Q1 FY25 weak, Q4 typically strongest.

Earnings-quality check — are profits backed by cash?

Financials — Balance Sheet, Cash Flow & Ratios

₹ Cr, standalone, 31-March year-ends. FY24–FY26 audited (FY25/FY26 ARs); FY22–FY23 from IP 5-year snapshot. FY22–23 gearing is flattering: OTS/ARC settlement dues (EARC, Exim, SBI London guarantee) sat in "other current liabilities", not debt.

Five-year balance sheet

FY26 "others" = other current liabilities 10.50 + other current financial liabilities 3.55 + current provisions 4.73 + current lease liabilities 6.71. Infomerics total debt FY24 109.27 (109.95 in Oct-24 release). Retained earnings still −₹42.6 Cr at Mar-26 (constrains distributable profit). FY26 PPE gross additions ₹31.6 Cr + ₹2.7 Cr software (SAP S/4HANA); freehold land ₹42.2 Cr; CWIP ₹25.4 Cr all <1 year old; capital commitments ₹16.6 Cr (FY25 ₹1.2 Cr). [Fact]

Inventory and receivables detail (FY26)

Five-year cash flow

FY25 restated OCF 26.20 (FY25 AR showed 26.10). FY24 financing: NCD inflow ₹95 Cr, loan repayment −₹49.3 Cr, warrant money ₹6 Cr, interest −₹34.7 Cr. Screener shows FY22 OCF 41 and FY23 FCF 7. IP capex tracker (management definition): FY24 ₹7 Cr, FY25 ₹48 Cr, FY26 plan ₹64 Cr (actual cash ₹59.1 Cr, ~92%), FY27 plan ₹63 Cr. Infomerics: cumulative FY25–27 capex ~₹150–160 Cr funded by accruals + NCDs, "no incremental term debt planned".

OCF bridge (audited; groupings by analyst)

1. FY24–26: cumulative PAT ₹127.1 Cr vs OCF ₹62.4 Cr (49%). Post-interest FCF ~−₹172 Cr; funded by ~₹147 Cr net borrowing (+45.7, +63.8, +37.5) and ~₹24 Cr promoter warrant + ESOP money.
2. Driver is working capital, not accruals: payables 162.7 → 107.2 (−₹55 Cr; creditor days 196 → 142) as stressed-era supplier credit normalised; receivables +₹54.5 Cr (debtor days 56 → 80); FY26 inventory +₹13 Cr, partly FG in transit ahead of launches.
3. Non-cash PAT: FY26 ₹6.98 Cr deferred-tax credit; FY22 ₹76.4 Cr exceptional ARC gain (cash was a settlement payment).
4. H1 FY26 OCF −₹5.66 Cr [Fact, IP] — absorption concentrated in H1.
5. Note 64 bank statements vs books: Sep-25 receivables reported to SBM ₹3.43 Cr below books; Dec-25 inventory ₹1.97 Cr above books and receivables ₹1.87 Cr lower — attributed to provisional pre-closing figures.

Working-capital days

[Est.] computed; payables include service creditors so creditor days are overstated in absolute terms (trend matters). AR ratios FY26 (FY25): inventory turnover 6.26x (7.99x), receivables turnover 5.05x (5.91x), payables turnover 2.36x (1.97x), net capital turnover 17.33x (31.84x). NWC up ~₹165 Cr since FY22, ~₹125 Cr since FY24. Stated credit terms 7–90 days yet ~63% overdue. Average WC utilisation 68% over 12 months to Dec-2025 (Infomerics).

Ratios

*FY22–23 distorted by settlement liabilities outside debt and near-zero/negative equity. AR-reported (Note 60) FY26/FY25: RoE 68.46%/70.01%; RoCE 25.37%/28.18%; D/E incl. leases 1.57x/3.02x; current ratio 1.19x/1.11x; DSCR 2.63x/2.12x. Infomerics expected ~3.6x interest coverage in FY26 (achieved 3.56x). Screener standalone shows RoE 68.4%, RoCE 30.7%. RoE is a small-denominator effect (FY25 equity ₹59.3 Cr; retained earnings −₹42.6 Cr), not a moat signal; RoE on FY26 closing equity is 45.8%. Q1 FY27 EBITDA/interest ~2.0x. Asset turnover is falling as capex and receivables outpace revenue.

Debt structure at 31-Mar-2026 (Notes 24 & 28)

• WC security: first pari-passu on current assets incl. brands; second charge on fixed assets; pledge of unencumbered promoter shares (Expert Chemicals, Kingsbury); pledge of 12.71 L Bravo Healthcare shares (related party) and 5 Wanbury Global FZE shares; corporate guarantees from Expert Chemicals, Bravo Healthcare, Wanbury Global FZE, Kingsbury; personal guarantee of K. Chandran.
• NCD face value (unreconciled): ₹175 Cr issued FY25 (1,750 NCDs, allotted 27-Feb-2025) + ₹25 Cr FY26 (250 NCDs) = ₹200 Cr; MGT-7 shows ₹200 Cr outstanding "decrease nil"; reconciliation implies ₹10 Cr repaid Feb-2026 → ~₹190 Cr face; carrying ₹186.4 Cr net of ~₹3.6 Cr unamortised costs. Amortisation uneven: AR current maturity ₹40 Cr FY27; Infomerics ₹35 Cr FY27, ₹42 Cr FY28, final ~Feb-2030.
• Contractual maturity (undiscounted, Note 58): ₹70.3 Cr within 1 year (incl. accrued interest), ₹147.2 Cr in 1–5 years, nil beyond. Infomerics expects gross cash accruals ₹80–120 Cr p.a.
• Covenants: no breach FY26/FY25 (Note 57); CARO: no default, not a wilful defaulter.
• Lenders: AR lists SBM Bank (India) and Emerging India Credit Opportunities Fund II (IDBI Bank exited after FY25). Infomerics attributes the NCD refinance to "Investec 175 cr NCD"; the Jun-2026 release says pledges were held by "Investec AIF and Tata Capital". Whether EICOF II and Investec are the same vehicle is unconfirmed — both shown. Tata Capital ₹60 Cr term loan taken and repaid within FY25.
• WC limit conflict: Infomerics rates a ₹40 Cr SBM cash credit; AR Note 64 says sanctioned WC limits are only ₹20 Cr (₹10 Cr FB + ₹10 Cr NFB) while drawn WC loans were ₹22.1 Cr. Unreconciled.
• Cost of debt: ~21–22.5% (Neo AIF) → 12.5% from 1-Mar-2025 → <10% from 1-Jul-2026.

Restructuring, OTS and ARC chronology

Credit rating history

• Upgrade drivers: sustained improvement FY25 & 9M FY26; capacity enhancement; yield improvement; E&Y process benchmarking; direct procurement; enhanced WC and factoring lines; new molecules (anaesthetic, anti-cough, diabetes, blood-thinner) from Q4 FY26; improved TOL/ATNW. Liquidity "Adequate": FY25 current ratio 1.11x, quick 0.89x; GCA ₹37.0 Cr FY25 vs ₹43.8 Cr FY24.
• Upgrade trigger: overall gearing <1.0x sustained. Downgrade triggers: weaker profitability/cash flows, delayed deleveraging, capex/launch slippage, adverse regulatory developments — Q1 FY27 and the Tanuku 483 test the "Stable" premise.
• Disclosure conflict: FY26 AR CG report item (r): "The Company does not have any credit rating programme" — contradicted by the live BBB-/Stable rating. The Dec-2025 INC episode (non-cooperation) is itself a disclosure flag. No CRISIL/ICRA/CARE/India Ratings rating found; NCDs appear unrated.

Equity dilution and share-count history

Share count +39.7% FY21→FY26 (2021 preferential ~31%, 2024–25 warrants ~6%). No QIP, rights or bonus; no buyback in 5 years (Note 22.6). MGT-7 "decrease 30,26,105" = physical-to-demat conversion, not capital reduction. ESOP 2016: 4,11,750 options outstanding (opening 4,65,000; granted 3,34,000; lapsed 2,18,350; exercised 1,68,900); 6,44,564 shares reserved (1.84%); most grants at ₹10 (deep in the money); 5-Feb-2026 grant of 60,000 at ₹130 (fair value ~₹70); FY26 ESOP expense ₹1.57 Cr; weighted diluted shares 3.4054 Cr; potential dilution ~1.2%; no warrants outstanding.

Other material financial disclosures

Key balance-sheet risks

• Debt up 97% in two years despite record profits; FCF negative; refinancing quantum and terms post-Jul-2026 undisclosed.
• Receivables quality: 63% past due, ECL only ₹0.51 Cr, factoring with recourse.
• Contingent liabilities ₹122.35 Cr unprovided vs ₹144.45 Cr net worth.
• Promoter shares and group guarantees embedded in the company's own credit structure.
• Thin equity (retained earnings −₹42.6 Cr) magnifies any write-down.

Management, Promoters & Governance

Primary sources: FY26 AR (38th; board report 29-May-2026; AGM 24-Sep-2026), FY25 AR (37th), FY26 MGT-7, AGM notice 11-Aug-2026. Overall governance risk: High-Medium

Promoter entities and beneficial ownership

Mohan Kumar Rayana ── 87.50% ──> Akkadian Trading & Marketing Pvt Ltd ──┐
                   └─ 87.50% ──> Gunbow Infotech & Datacom Pvt Ltd ───────┤ 50% + 50%
K. Chandran ─────────── 9.90% of each holding company                    ▼
(~2.6% of each held by undisclosed holders)          Expert Chemicals (India) Pvt Ltd ── 34.36% ──> WANBURY
Kingsbury Investments Inc (owner undisclosed) ─────────────────────────────── 8.66% ──> WANBURY

Look-through [Est.]:  Rayana ≈ 87.5% × 34.36% ≈ 30.1%    Chandran ≈ 9.9% × 34.36% ≈ 3.4%

Promoter / director profiles

Key managerial personnel

No CEO or MD — run by two promoter-linked WTDs (both 68–69, no disclosed succession), with professional presidents for API (Prakash Venkatraman) and formulations (Rashesh Patel). No KMP changes in FY26. Headcount 1,382 → 1,211 (−12%) while managerial pay rose from nil.

Board of directors

• Six directors: 2 executive, 4 independent (67%); no NEDs or nominees. Executive chairman → ≥50% independent required — met. Seven board meetings in FY26 (15-May, 23-Jun, 4-Aug, 18-Sep, 13-Nov, 10-Dec-2025; 5-Feb-2026); all decisions unanimous.
• Sitting fees ₹40.25 L FY26 (≈₹26 L FY25, ≈₹29 L FY24) — ~₹10–11 L per ID is rich for a ₹650 Cr company; fee-dependence risk [Est.].
• Short/rolling ID terms: Pravin Dilip Pawar served exactly one year (18-Nov-2023 to 17-Nov-2024; "retired" per board report, "resigned" per secretarial audit); Gursahani on a one-year renewal.
• Board churn: Pallavi P. Shedge (ID) left 13-Feb-2024 and N.K. Puri (ID) 31-Mar-2024 at end of tenure; board fell below six-director minimum; Reg 17(1)/19 breaches from ~Q1 FY24 to Q3 FY25; compliance restored 8-Jan-2025.

Shareholding pattern — trend (% of equity)

Notable public holders (≥1%)

Emkay table labelled 30-Jun-2026 but on the pre-conversion 3.29 Cr base (likely Jun-2025). MFs hold 895 shares, banks 521 (MGT-7). Physical shares 9.91% (Mar-25) → 0.64% (Mar-26). Rejected: Simply Wall St "SBI asset management arm 9,913,304 shares (30.3%)" — feed error (≈ size of pledged promoter block; SHP shows MF ~0%). No marquee investor (Kacholia, Kedia, Agrawal, Dolly Khanna) in any ≥1% list.

Promoter pledge — UNRESOLVED (sources conflict; this report does not pick one)

Interpretation [Est.]: most of the promoter stake (60–87%) was encumbered to support the company's own borrowings, not promoter-level debt. The Jun/Jul-2026 releases and the NBFC refinance may have reset it. ScanX's "acquirer is not part of the promoter group" refers to the pledgee (Catalyst) filing as acquirer.

Warrants, SAST and insider activity

Related-party transactions

Related parties (Note 56): significant influence — Expert Chemicals; subsidiaries until 1-Apr-2025 — Wanbury Holding B.V., Cantabria Pharma S.L., Ningxia Wanbury Fine Chemicals, Wanbury Global FZE; KMP-controlled — Wanbury Infotech Pvt Ltd, Bravo Healthcare Ltd, Wanbury Pharma Ltd (all use the "Wanbury" name); relative of KMP — Anisha Rayana.

Bravo Healthcare — circular arrangement: Wanbury holds 12,71,250 Bravo shares (cost ₹53.40 L, fully impaired) pledged to its own lenders, while Bravo guarantees Wanbury's WC debt. Bravo co-founded the Ningxia China sourcing venture (2008). Bravo's business and ownership are undisclosed. The company states all RPTs are at arm's length, none above 1% of revenue, no material RPT. Managerial-pay inconsistency: Note 50 says no managerial remuneration was paid in FY25, while Annexure IV cites a "2.75%" increase in FY26.

Auditors

Subsidiaries, group structure and acquisition track record

Lifetime cost of the overseas and group forays ≈ ₹180 Cr+ before interest, ARC haircuts and guarantees — larger than FY26 net worth. (market.md's mapping labels 100.04 as WHBV investment and 38.49 as Ningxia; governance.md §8.2's mapping, used here, is consistent with AOC-1 capital figures.) Inconsistent disclosures: FY25 AR (15-May-2025) still listed four live subsidiaries; board "noted" deregistration only on 4-Aug-2025; the 4-Aug-2025 intimation (TipRanks) said they "had never started operations" — false for Cantabria and WHBV.

Litigation, tax and regulatory matters

CARO FY26 disputed dues (net of deposits, ₹ L): CST 42.95 (FY1997–2005, AP High Court); service tax 102.61 and 71.98 (CESTAT Mumbai; Commissioner Raigad); GST 2,724.49 (FY2017-18) plus 33.32, 39.76, 81.64, 129.21, 17.24, 4.57 (Appellate Authority Maharashtra; Dy Commissioner AP; Jaipur; Odisha); income tax 397.76, 1,358.05, 1,075.89, 51.98, 148.15 (FY2016-17 to FY2023-24; CIT(A), ITAT). Paid under protest ~₹0.45 Cr total (IT ₹0.13 Cr; GST ₹0.21 Cr). Management: all demands "not tenable"; no provision. ~₹56 Cr of new disputes in one year ≈ 8% of market cap.

FY26 CG report: "no instances of non-compliance… relating to capital markets during the past three years" (item XIV mentions only "some penalties"); FY25 AR: "no non-compliances". MGT-7 FY26 errors: WTD/KMP pay "Nil" (vs ₹2.81 Cr); "0 members' meetings" (EGM 5-Jan-2026 and 2025 AGM held); Mehta 0 shares. No SEBI order; no director debarred; no IBC, wilful-defaulter or going-concern-affecting orders.

Governance red-flag register

Open governance items: Sep-2026 pledge status; berrysoft subsidiary CIN/ownership/consideration; NBFC lender terms; Kingsbury UBO and ~2.6% of holdcos; Bravo/Wanbury Infotech/Wanbury Pharma ownership; 2021 preferential allottees; CFO/CS/ID backgrounds; predecessor auditor; AGM 24-Sep-2026 vote results; PIT/SAST logs.

Supply Chain

Upstream dependencies and downstream customers. Wanbury names no suppliers and no top-5/top-10 customer shares; where the company is silent, route chemistry and filings are used and tagged [Est.].

↑ Upstream — What Wanbury Depends On

↓ Downstream — Who Depends On Wanbury

End-products containing Wanbury's output [Est., from pharmacology]

Value-chain map

Petrochemicals / basic chemicals                          (China, India)
  -> KSMs & intermediates: DCDA, dimethylamine HCl,        ~27% imported (FY26)
     sertraline tetralone, 3-bromoanisole,                 advance-licence duty-free
     piperidine intermediates, solvents (methanol, etc.)
        |
        v
WANBURY  (Tanuku ~400 KL multi-purpose; Patalganga ~96 KL metformin/DC)
  - synthesis, chiral resolution, polymorph control, DC granulation
  - DMF/CEP/CADIFA dossiers (70 filings: 64 approved + 6 under review) = regulatory moat
        |                                               \
        v                                                v
Generic formulators (Teva/Mylan/Apotex [3rd-party],     Wanbury branded formulations (India)
  Brazil generics, EU/Korea/Australia makers)             outsourced contract manufacturers
  -> ANDAs / MAs reference the Wanbury DMF                -> 17 C&F -> 1,800+ distributors
        |                                                     -> chemists -> 30,000+ doctors
        v                                                        |
Wholesalers / PBMs / tenders / pharmacies                        v
        |                                                    Indian patients (acute, OTC-like)
        v
Patients: type-2 diabetes (metformin), depression (sertraline, paroxetine),
pain (tramadol, mefenamic), allergy/sleep (DPH), anaesthesia

Where pricing power sits

Competitive Position

Peer figures consolidated, from Screener as of 13-Oct-2026 ~11:00 IST, recomputed (P/E = mcap ÷ FY26 PAT; RoE on FY26 closing equity; peer EV = mcap + borrowings − investments, peer cash not netted so slightly overstated). Wanbury standalone; Wanbury row uses this report's reconciled values.

Market position

Peer comparison (FY26)

*Wanbury RoE: 45.8% on closing equity / 64.9–68.5% on average equity — small-denominator distortion (retained earnings −₹42.6 Cr). market.md's Wanbury row used FY26 rather than TTM and mcap ₹669 Cr: P/E 10.1x (14.1x normalised; TTM ~12.0x), EV/EBITDA 8.2x (TTM 8.9x) on EV ₹876.8 Cr — this report uses financials.md's TTM basis (EV ~₹884 Cr incl. leases). Peer selection: Aarti (most direct metformin overlap), Granules (metformin PFI scale), IOL (commodity API), Supriya (DPH/anaesthetic niche exporter), Kopran (similar size and model). Hikal shows loss-making API names still trade at mid-teens EV/EBITDA.

Strengths and weaknesses vs each peer [Est.]

Industry size, growth and trends

Metformin HCl price tracker (US$/kg, Expert Market Research)

H2-2026 global forecast US$9.72–10.68/kg ("moderately firm"). Indian metformin carries a ~US$3–3.5/kg (~45–50%) premium over Chinese [Est.] — durable only while buyers value USFDA/EDQM status, nitrosamine control and supply security. Named producers (unverified lists): USV (India, private), Wanbury, Aarti Drugs, Granules, IOL; China: Shouguang Fukang, Keyuan, Shandong Lukang. NDMA barrier: Dec-2019 FDA flagged NDMA in non-US metformin; May–Jul 2020 ER recalls (Amneal, Actavis, Apotex, Lupin, Marksans, Bayshore); Sep-2024 revised FDA nitrosamine guidance — a quality moat for validated producers and a recurring cost/recall risk.

Key industry trends [Est.]

1. China+1 de-risking supports Indian regulated-grade APIs — Wanbury's USFDA, EDQM, ANVISA, KFDA, TGA, WHO-GMP filings (64 approved + 6 under review) are a real asset.
2. Nitrosamine/genotoxic-impurity tightening raises the bar but can trigger recalls.
3. Consolidation of API supply into ICH Q7-qualified plants (IndexBox).
4. Chinese surplus capacity pressures commodity molecules such as metformin.
5. Domestic tightening: FDC bans, paediatric cold-combination restrictions, Revised Schedule M, UCPMP, cough-syrup scrutiny.
6. Indian mid-caps moving to higher-value APIs (anaesthetics, DPP-4, anticoagulants) — sitagliptin and rivaroxaban already crowded with dozens of Indian DMF filers.

Government policy and regulation

Barriers to entry, Porter's Five Forces, moat [Est.]

Risks & Red Flags

Comprehensive register (business, financial, regulatory, governance, macro, execution, ESG, market). Severity reflects the analyst's view as of 13-Oct-2026. Credit-rating rows updated to the verified Infomerics IVR BBB-/Stable (5-Mar-2026).

Risk register

Red-flag checklist

Concall Highlights & Guidance

Coverage window Oct-2024 to Oct-2026. No earnings-call transcripts were found and none are reproduced or invented. This tab is built from company releases, the Nov-2025 investor deck, the FY26 AR and AGM notice, and exchange filings.

Disclosure and communication record

Quarter-by-quarter ledger (last 6 quarters plus context)

Management's own words, by theme

Growth

• Nov-2025 (Q2 deck, Mohan Kumar Rayana): "Q2 continues to be stronger with EBITDA achievement of ₹26.0 (16.2%) crore as compared to 21.6 (13.3%) crore in Q2 FY25… PAT of ₹15.2 crore as compared to ₹8.0 crore… robust growth of approx. 90% led by cost efficiencies, improved Product yield & lower finance cost." [Fact]
• Nov-2025 deck summary: "Successful turnaround to growth momentum… Operational & financial turnaround over last 2 years, now transforming into growth momentum." "…launch of an Anaesthetic in Q4, and pipeline of 4 molecules commercialisation each year beginning next financial year."
• 28/30-Jan-2026 (Tanuku launch, Rayana): "We are excited about this strategic expansion…"; "This versatile new API is expected to generate incremental revenues for Wanbury in FY 2026-27"; "First sales confirmed, invoicing and product shipment completed, production scaling fast." Facility covers anti-tussive, anti-coagulant, anaesthetic, antidepressant molecules; "₹100.00 crore from these anaesthetic APIs by FY 2026-27", ~15% of annual revenue (ScanX); Indian Pharma Post frames ~₹100 Cr as the facility's. [Third-party quoting release]
• 6-Feb-2026 (Q3, Rayana): "Q3 FY26 revenue grew 22 per cent year-on-year and 9M FY26 revenue grew 14 per cent… driven by strong demand and higher volumes in our API business alongside moderate but steady growth in formulations." "…shipment of a high-potency anaesthetic API to a European customer from our cutting-edge Tanuku facility in Q3 FY26." "With upcoming launches in antidiabetic, anticoagulant, cough suppressant and antidepressant APIs… well positioned for growth."
• FY26 AR MD&A (29-May-2026): "Both Metformin and Sertraline continued to do well with strong order book positions with existing and new customers, growing in line with industry. Metformin Direct compression grade saw a growth of 7% in volume."
• 11-Aug-2026 (Q1 FY27, Rayana): "Q1 FY27 was a quarter marked by an unprecedented increase in input costs." "We view these pressures as transitory and specific to the input cost environment prevailing during the period." New Tanuku block "being validated and commercialised"; volume growth expected.

Margins

• Nov-2025: improvement "driven by several technical initiatives including enhanced product yields and higher solvent recoveries… procurement efficiencies — such as improved negotiations through auction-based sourcing for large-volume raw materials and longer period suppliers' contracts for KSM." API target "~50% gross margins"; "50%+ Gross contribution margins".
• FY26 AR: "Uninterrupted supply along with stable pricing of raw materials and continuous cost reduction initiatives in manufacturing resulted in better margins." On pricing: "able to overcome this risk by influencing the prices, as it is one of the largest manufacturers of Metformin in the world."
• Aug-2026 outlook: full pass-through of input inflation in Q2; gross and EBITDA margins to recover from Q2; finance-cost benefit from Q2 FY27.

Concerns management itself flagged (FY26 AR "Threats")

• "A majority of revenue is export-oriented, exposing the Company to regional disruptions (as seen in the West Asia-related impact on Formulations exports in FY 2025-26)…"
• Leverage: "… term debt (Rs. 215.45 crore as of 31st March 2026)".
• Two-molecule dependence: 4 new molecules a year "aimed at reducing dependency on Metformin and Sertraline".
• Formulations regulation: DCGI CPM + phenylephrine FDC restriction (<4 yrs) → Coriminic CPM Drops and NS Nasal Drops.

Contradictions in management communication

Tone trajectory

Guidance vs actual — credibility ledger

Recurring themes: yield/solvent/procurement as the margin engine; two-molecule dependence with diversification always "next year"; deleveraging as the equity story; anaesthetic + new block as the growth bridge; external factors (West Asia) explaining two straight disappointments. Credibility score: Medium [Est.] — balance-sheet promises delivered; operating promises slipped within two quarters.

Questions an analyst would ask (document-derived substitute for Q&A)

Growth, Outlook & Valuation

Order visibility and outlook from company commentary; valuation per the financials module (TTM basis, CMP ₹191, 3.4939 Cr shares, mcap ~₹667 Cr). No broker coverage exists; "targets" shown are non-institutional.

Order book and revenue visibility

Expansion plans and capex

• Capacity: ~500 KL → ~600 KL potential at existing sites (+~100 KL brownfield at Tanuku's 18 acres; Patalganga fully occupied). Patalganga DC line 70 → 140 MT. 1.5 MW Satara solar (no update).
• New markets: DMFs in South Africa, Philippines, Singapore, Malaysia, Korea, LatAm; TGA GMP certificate (3 more APIs to Australia, pending); China NMPA (two APIs registered, third expected); "explores new API business opportunities in South Korea" (Jul-2026).
• New products: anaesthetic (launched), rivaroxaban (CEP), quetiapine, DXM HBr, imeglimin, sitagliptin, montelukast; formulations into paediatrics, dermatology, cardio-diabetes; berrysoft baby range via Wanbury Skin Health Ltd.
• Infomerics: ₹60–70 Cr of incremental annual revenue from new molecules.

Catalysts (next 12 months)

Long-term drivers (3–5 years) and tailwinds

• China+1 sourcing shift and nitrosamine-driven consolidation into qualified Indian plants (metformin regulated-grade premium 30–60%).
• Metformin volume +3–5% p.a. to 2035; combinations 30% → 40–50% of use (DC-grade relevance).
• Niche molecule strategy (small-mid volume, double-digit share, ~50% GM) and supplying patented molecules' chains "beyond FY29–30".
• Lower cost of capital (<10%) and potential rating upgrade (trigger: gearing <1.0x).
• Policy: PLI bulk-drug KSM capacity (DCDA) could reduce China dependence; Bulk Drug Park in AP (neutral). Wanbury is not a PLI beneficiary.

Management guidance (numbers given)

Analyst consensus and coverage

AI models cut targets ~17% and cluster at ₹193–216 (mechanical Holds). Univest ₹330 pre-dates the 483 and Q1 miss — stale and gives no method ("for illustration only and not recommendatory"); its thesis: FY27 PAT growth 15–20%, API/PLI tailwinds, RBI rate cuts, FII re-entry; risks: tariffs, FY27 miss, competition from Divi's/Solara, liquidity. Non-broker range ₹193–400, median ~₹240–250 — not a consensus. Other street datapoints: Mojo P/E 16x vs industry 36x; Univest P/E 13.6x vs sector median 32x; forum PEG ~0.5, EV/EBITDA ~9.5x.

Street sentiment, media and forums

Sentiment shift: Apr → mid-Jul 2026 euphoria (deleveraging news, record FY26, breakout narratives, ₹360 high, retail count rising again) → late-Jul → Oct capitulation (483 on 22-Jul, Q1 miss 11-Aug, quant downgrades, −8.9% on 30-Sep, death cross 5-Oct; −36% over 3 months). AI targets now converge at CMP and no human broker defends the stock. Recurring debates: deleveraging vs leverage; FY26 vs Q1 FY27; regulatory record vs 483; valuation (P/E vs sector) vs governance discount; mix shift vs commodity pressure. [Est.]

Valuation — current vs history

[Est.] Monthly averages: FY25 ~₹215 (P/E 23.0x); FY26 ~₹255 (13.1x reported, ~18.3x normalised). FY26 AR caps FY26 high at ₹330 (May-2025); Oct-25–Mar-26 peak ~₹284. Read: below 3-yr average on reported P/E and EV/EBITDA; roughly in line on normalised P/E; P/B de-rated because book grew 5x (early P/B meaningless). Stale aggregator figures not used: P/E 15.6x and P/B 10.6–11.3x on BV ₹18 (Screener consolidated FY25), D/E 2.77x (Mojo); Univest P/B 5.17x / BVPS ₹41.96. Peer multiples: 14–23x EV/EBITDA, 19–47x P/E (Tab 9).

Price performance

Illustrative scenario valuation [Analyst View] [Est.]

Net debt assumed at Mar-26 level (~₹208 Cr, excl. leases) since post-refinance debt is undisclosed; 3.4939 Cr shares. Multiples bracket Wanbury's own 3-year range (8.5–12.2x) and sit below the peer range (14–23x) given governance and concentration. Not a price target — a sensitivity frame.

Dividends and buybacks

No dividend since FY2009-10 (unclaimed ₹4.15 L and 3.38 L shares transferred to IEPF); no dividend recommended for FY26; retained earnings −₹42.6 Cr constrain distributions; no buyback in five years (Note 22.6); payout 0% every year (Screener: "Repeated profits but no dividend"). [Fact]

Final Verdict

Analyst synthesis across all inputs. [Analyst View]

Sources

Merged and de-duplicated from the Sources lists of all seven inputs (financials, business, governance, narrative, market, street-sentiment, lead-analyst primary verification). All accessed 13-Oct-2026 unless noted; publication dates shown where known. "AI/secondary" marks aggregator content that is AI-generated or AI-assisted — directional only.

Source authority used for reconciliation

1. Company filings, annual reports and presentations

2. Exchange announcements and company press releases

3. Credit ratings

4. Financial and market data

5. Shareholding and pledge

6. News, media and company-event coverage

7. Industry and regulatory references

8. Forums and social

9. Research gaps and limitations (carried from all inputs)

Local working extracts referenced by the input modules (wan_ar26.txt, wan_ar25.txt, wan_ip.txt, wan_mgt7.txt; saved Infomerics and BSE PDFs in the session tool-results folder) are derived from the URLs above. Report prepared for Aamara Capital, 13 Oct 2026. For internal use only.